Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Outbreak monitoring & surveillance stories

Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Oct 5, 2026

CDC warns of sharp rise in deadly brain fungal infections from Cladophialophora bantiana

The CDC is calling for increased surveillance after a clinical reference laboratory detected a sharp rise in cases of Cladophialophora bantiana, a rare fungus that attacks the brain and carries a 60-70% fatality rate. Scientists are uncertain about the cause of the increase, which has been observed even in otherwise healthy patients.

Oct 5, 2026·5 sources
00
Sep 30, 2026

Infections caused 2.3 million cancer cases globally in 2024, study finds

The International Agency for Research on Cancer reported that infections were responsible for 2.3 million new cancer cases in 2024, representing 12% of all global cancer diagnoses. Helicobacter pylori, HPV, hepatitis B and C, and Epstein-Barr virus were the primary infectious causes.

Sep 30, 2026·3 sources
00
Sep 28, 2026

Merck discontinues Recarbrio antibiotic despite concerns over superbug resistance

Merck has discontinued Recarbrio, a crucial antibiotic used to treat drug-resistant infections, raising concerns among health experts about the availability of treatments for superbug resistance at a time when antimicrobial resistance remains a growing public health threat.

Sep 28, 2026·2 sources
00
May 26, 2026

Eli Lilly Acquires Three Vaccine Developers, Expanding Infectious Disease Portfolio

Eli Lilly is acquiring three small vaccine developers, marking a significant expansion into infectious disease vaccines and providing a boost to the vaccine development field.

May 26, 2026·1 source
00
Apr 21, 2026

WHO-Recommended Antibiotics Effective in Only 25% of Neonatal Sepsis Cases in Low- and Middle-Income Countries

A major multi-country study found that WHO-recommended first-line antibiotics for neonatal sepsis are likely to be effective in only one-quarter of infections in low- and middle-income countries, highlighting a critical gap in global infant health treatment protocols.

Apr 21, 2026·1 source
00

Top claims

  • ▪Prescribing warnings for Hibsago include risks of deteriorating kidney function, serious inflammatory adverse reactions such as vasculitis, and complications from improper injection
  • ▪Patients using Hibsago require regular blood tests during therapy to monitor for hepatic flares, reduced platelet counts, and kidney function risks
  • ▪Hibsago has secured regulatory approval in Japan and is under regulatory review by health authorities in China and Europe

Subtopics

Infectious disease6Infectious Disease and Outbreaks2Pharmaceutical Industry2Antimicrobial resistance1Antiviral therapy1Chronic disease management1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1Eli Lilly1Epidemiology1FDA drug approval1FDA regulatory approval1Global health1Healthcare industry1Hepatitis B treatment1Outbreak-Driven Vaccination1Pharma1Preventive medicine1Public health1Reproductive Health1Vaccines and Immunization Policy1

Related timelines

Iran War

209 stories

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Russia-Ukraine war

136 stories